This is an old revision of this page, as edited by Mo18ekula (talk | contribs) at 14:26, 17 December 2024. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 14:26, 17 December 2024 by Mo18ekula (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Identifiers | |
---|---|
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C17H15N3 |
Molar mass | 261.328 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
To treat diabetes. The design is an attempt to generate an analog of Idazoxan.
The structure is a Imidazoline and also an N-phenylindole.
Synthesis
Prec: Patent:
Ex 1: The reaction between ethyl 1-phenyl-1H-indole-2-carboxylate (1) and ethylenediamine (2) gives RX 871024 (3). Also, reaction of 1-phenylindole-2-carbonitrile, PC20095505 with ethylenediamine monotosylate gives higher yield.
References
- Denis Bigg, et al. US4659731 (1987 to Synthelabo SA).
- Fagan, Gay P.; Chapleo, Christopher B.; Lane, Anthony C.; Myers, Malcolm; Roach, Alan G.; Smith, Colin F. C.; Stillings, Michael R.; Welbourn, Anthony P. (1988). "Indoline analogs of idazoxan: potent .alpha.2-antagonists and .alpha.1-agonists". Journal of Medicinal Chemistry. 31 (5): 944–948. doi:10.1021/jm00400a009.
- Dolby, Lloyd J.; Lord, Pierre D. (1969). "2-Alkylidene-2H-indole intermediates. Thermolysis of 2-hydroxydiphenylmethylindole". The Journal of Organic Chemistry. 34 (10): 2988–2993. doi:10.1021/jo01262a042.
- Christopher B. Chapleo & Gay P. Fagan, US5385919 (1995 to Reckitt & Colman Products Limited).